Advanced Glycation End Products and Receptor-Oxidative Stress System in Diabetic Vascular Complications

被引:46
作者
Yamagishi, Sho-ichi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan
关键词
Advanced glycation end product; Advanced glycation end product receptor; Diabetic vascular complications; Oxidative stress; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR PEDF; THERAPEUTIC TARGET; RETINAL PERICYTES; INDUCED APOPTOSIS; VITREOUS FLUID; RENAL-FAILURE; NEPHROPATHY; EXPRESSION;
D O I
10.1111/j.1744-9987.2009.00775.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reducing sugars can react non-enzymatically with amino groups of protein to form Amadori products. These early glycation products undergo further complex reactions, such as rearrangement, dehydration, and condensation, to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end products (AGEs). The formation and accumulation of AGEs have been known to progress at an accelerated rate in patients with diabetes mellitus, thus being involved in the development and progression of diabetic micro- and macroangiopathy. Indeed, there is accumulating evidence that an interaction between an AGE and its receptor (RAGE) generates oxidative stress and subsequently evokes vascular inflammation and thrombosis, thereby playing a central role in diabetic vascular complications. In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic micro- and macroangiopathy.
引用
收藏
页码:534 / 539
页数:6
相关论文
共 26 条
[1]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[2]   Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J].
Nathan, DM ;
Cleary, PA ;
Backlund, JYC ;
Genuth, SM ;
Lachin, JM ;
Orchard, TJ ;
Raskin, P ;
Zinman, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2643-2653
[3]   TAGE (toxic AGEs) theory in diabetic complications [J].
Sato, Takashi ;
Iwaki, Mina ;
Shimogaito, Noriko ;
Wu, Xuegang ;
Yamagishi, Sho-ichi ;
Takeuchi, Masayoshi .
CURRENT MOLECULAR MEDICINE, 2006, 6 (03) :351-358
[4]   PEDF: A multifaceted neurotrophic factor [J].
Tombran-Tink, J ;
Barnstable, CJ .
NATURE REVIEWS NEUROSCIENCE, 2003, 4 (08) :628-636
[5]   Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure [J].
Ueda, Seiji ;
Yamagishi, Sho-ichi ;
Takeuchi, Masayoshi ;
Kohno, Keisuke ;
Shibata, Ryo ;
Matsumoto, Yuriko ;
Kaneyuki, Utako ;
Fujimura, Toshiko ;
Hayashida, Ayako ;
Okuda, Seiya .
MOLECULAR MEDICINE, 2006, 12 (7-8) :180-184
[6]   Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients [J].
Uribarri, J ;
Peppa, M ;
Cai, WJ ;
Goldberg, T ;
Lu, M ;
Baliga, S ;
Vassalotti, JA ;
Vlassara, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (03) :532-538
[7]   Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy [J].
Wang, JJ ;
Zhang, SX ;
Lu, KM ;
Chen, Y ;
Mott, R ;
Sato, S ;
Ma, JX .
DIABETES, 2005, 54 (01) :243-250
[8]   Salutary effect of pigment epithelium-derived factor in diabetic nephropathy - Evidence for antifibrogenic activities [J].
Wang, Joshua J. ;
Zhang, Sarah X. ;
Mott, Robert ;
Knapp, Ryan R. ;
Cao, Wei ;
Lau, Kai ;
Ma, Jian-xing .
DIABETES, 2006, 55 (06) :1678-1685
[9]   RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy [J].
Wendt, TM ;
Tanji, N ;
Guo, JC ;
Kislinger, TR ;
Qu, W ;
Lu, Y ;
Bucciarelli, LG ;
Rong, LL ;
Moser, B ;
Markowitz, GS ;
Stein, G ;
Bierhaus, A ;
Liliensiek, B ;
Arnold, B ;
Nawroth, PP ;
Stern, DM ;
D'Agati, VD ;
Schmidt, AM .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1123-1137
[10]   Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy [J].
Yamagishi, S ;
Imaizumi, T .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (18) :2279-2299